Product/Composition:- | Rucaparib Camsylate |
---|---|
Strength:- | 200 mg, 250 mg, 300 mg |
Form:- | Oral tablets |
Reference Brands:- | Rubraca® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Rucaparib Camsylate is a PARP inhibitor used for treating ovarian, fallopian tube, and peritoneal cancers, particularly those with BRCA mutations. Marketed under Rubraca®, it is available in 200 mg, 250 mg, and 300 mg oral tablets. Manufactured in GMP-compliant facilities, Rucaparib offers a targeted approach to cancer treatment and is a reliable choice for pharmaceutical distributors in US and EU markets.
Rucaparib Camsylate is an innovative PARP inhibitor used in the treatment of ovarian, fallopian tube, and peritoneal cancers. This targeted therapy is especially effective in cancers with BRCA mutations, as it disrupts DNA repair mechanisms in cancer cells, leading to their destruction. Available under the brand name Rubraca®, it is offered in 200 mg, 250 mg, and 300 mg oral tablet strengths. Manufactured under GMP-certified conditions, Rucaparib is a trusted solution in oncology care. Ideal for US and EU pharmaceutical distributors and wholesalers, it provides an advanced treatment option in precision medicine for cancer patients.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications